Literature DB >> 3409636

Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man.

V Mavichak1, C M Coppin, N L Wong, J H Dirks, V Walker, R A Sutton.   

Abstract

1. The renal handling of calcium and magnesium was studied in six patients with persistent hypomagnesaemia after cis-platinum treatment for testicular tumours. 2. In comparison with normal subjects, the patients showed hypomagnesaemia (mean 0.54 mmol/l), which was associated with a normal urinary magnesium excretion (mean 4.83 mmol/24 h). Urinary calcium excretion was significantly lower in the patients than in the normal subjects (mean 2.05 vs 5.15 mmol/24 h, respectively; P less than 0.01), despite slightly higher total serum calcium levels (2.53 vs 2.38 mmol/l, respectively; P less than 0.05). During magnesium chloride infusion, when serum magnesium levels were comparable in patients and controls, urinary calcium excretion remained lower in the patients, indicating that hypomagnesaemia was not the cause of the hypocalciuria. 3. Dietary magnesium supplementation resulted in a significant increase in the serum magnesium levels in the patients, while dietary magnesium deprivation resulted in a comparable decrease in urinary magnesium excretion in patients and controls (to 1.46 and 2.00 mmol/day, respectively), although the serum magnesium level fell further (to 0.46 mmol/l) in the patients. 4. The dissociation of renal calcium and magnesium excretion appears to be part of the intrinsic tubular defect caused by cis-platinum. This dissociation of urinary calcium and magnesium excretion, which resembles that seen in Bartter's syndrome, may result from a lesion in the distal convoluted tubule.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409636     DOI: 10.1042/cs0750203

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

Review 1.  Renal magnification by EGF.

Authors:  David H Ellison
Journal:  Nephrol Dial Transplant       Date:  2008-02-25       Impact factor: 5.992

Review 2.  Distal convoluted tubule.

Authors:  James A McCormick; David H Ellison
Journal:  Compr Physiol       Date:  2015-01       Impact factor: 9.090

3.  Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin.

Authors:  M G Bianchetti; C Kanaka; A Ridolfi-Lüthy; H P Wagner; A Hirt; L Paunier; E Peheim; O H Oetliker
Journal:  Pediatr Nephrol       Date:  1990-05       Impact factor: 3.714

Review 4.  Testicular cancer survivorship: research strategies and recommendations.

Authors:  Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Journal:  J Natl Cancer Inst       Date:  2010-06-28       Impact factor: 13.506

5.  Investigation of the efficacy of 99 mTc-DTPA scintigraphic GFR measurement with Gates method in the detection of cisplatin-induced nephrotoxicity in comparison with plasma urea and creatinine measurement.

Authors:  Filiz Özülker; Tamer Özülker; Aysun Küçüköz Uzun; Tevfik Özpaçacı
Journal:  Med Oncol       Date:  2010-05-14       Impact factor: 3.064

Review 6.  Gitelman-like syndrome after cisplatin therapy: a case report and literature review.

Authors:  Kessarin Panichpisal; Freddy Angulo-Pernett; Sharmila Selhi; Kenneth M Nugent
Journal:  BMC Nephrol       Date:  2006-05-24       Impact factor: 2.388

7.  PIP2 activates TRPV5 and releases its inhibition by intracellular Mg2+.

Authors:  Jason Lee; Seung-Kuy Cha; Tie-Jun Sun; Chou-Long Huang
Journal:  J Gen Physiol       Date:  2005-10-17       Impact factor: 4.086

8.  Effect of Oral Magnesium Oxide Supplementation on Cisplatin-Induced Hypomagnesemia in Cancer Patients: A Randomized Controlled Trial.

Authors:  Maryam Zarif Yeganeh; Masoud Vakili; Ali Shahriari-Ahmadi; Marzieh Nojomi
Journal:  Iran J Public Health       Date:  2016-01       Impact factor: 1.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.